Latest News

Senhwa’s Abstract of Silmitasertib for the Treatment of Basal Cell Carcinoma Clinical Trial Accepted for 2020 ASCO Online Publication

May

14

2020

Senhwa Biosciences Silmitasertib Named as Potential Covid-19 Therapy

Mar

31

2020

Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS

Dec

13

2019

Senhwa Biosciences Silmitasertib / Medulloblastoma Trial Completed 1st Patient Enrollment

Jul

25

2019

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

May

02

2019

Senhwa Biosciences Silmitasertib of Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Apr

17

2019

Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA

Nov

01

2018

PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment

Jun

12

2018